Abstract CT559: Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification
Year: 2022
Type: conference-abstract
Source: Cancer Research
Institutions: Guangdong Provincial People's Hospital, National Cancer Center, Kanagawa Cancer Center, Institut Gustave Roussy, University of California, Los Angeles, Instituto Nazionale Tumori Regina Elena, National Cancer Center Hospital East, Novartis (Switzerland), National Cancer Centre Singapore
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4283377098